Interferon-β 1a and SARS Coronavirus Replication

Lisa E. Hensley, Elizabeth A. Fritz, Peter B. Jahrling, Christopher L. Karp, John W. Huggins, Thomas Geisbert

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon -β 1a potently inhibits SARS coronavirus replication in vitro.

Original languageEnglish (US)
Pages (from-to)317-319
Number of pages3
JournalEmerging Infectious Diseases
Volume10
Issue number2
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Severe Acute Respiratory Syndrome
Coronavirus
Interferons
Antiviral Agents
Disease Outbreaks
Public Health

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Hensley, L. E., Fritz, E. A., Jahrling, P. B., Karp, C. L., Huggins, J. W., & Geisbert, T. (2004). Interferon-β 1a and SARS Coronavirus Replication. Emerging Infectious Diseases, 10(2), 317-319.

Interferon-β 1a and SARS Coronavirus Replication. / Hensley, Lisa E.; Fritz, Elizabeth A.; Jahrling, Peter B.; Karp, Christopher L.; Huggins, John W.; Geisbert, Thomas.

In: Emerging Infectious Diseases, Vol. 10, No. 2, 02.2004, p. 317-319.

Research output: Contribution to journalArticle

Hensley, LE, Fritz, EA, Jahrling, PB, Karp, CL, Huggins, JW & Geisbert, T 2004, 'Interferon-β 1a and SARS Coronavirus Replication', Emerging Infectious Diseases, vol. 10, no. 2, pp. 317-319.
Hensley LE, Fritz EA, Jahrling PB, Karp CL, Huggins JW, Geisbert T. Interferon-β 1a and SARS Coronavirus Replication. Emerging Infectious Diseases. 2004 Feb;10(2):317-319.
Hensley, Lisa E. ; Fritz, Elizabeth A. ; Jahrling, Peter B. ; Karp, Christopher L. ; Huggins, John W. ; Geisbert, Thomas. / Interferon-β 1a and SARS Coronavirus Replication. In: Emerging Infectious Diseases. 2004 ; Vol. 10, No. 2. pp. 317-319.
@article{61e127163d44411a867a2d46e6c8bc86,
title = "Interferon-β 1a and SARS Coronavirus Replication",
abstract = "A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon -β 1a potently inhibits SARS coronavirus replication in vitro.",
author = "Hensley, {Lisa E.} and Fritz, {Elizabeth A.} and Jahrling, {Peter B.} and Karp, {Christopher L.} and Huggins, {John W.} and Thomas Geisbert",
year = "2004",
month = "2",
language = "English (US)",
volume = "10",
pages = "317--319",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "2",

}

TY - JOUR

T1 - Interferon-β 1a and SARS Coronavirus Replication

AU - Hensley, Lisa E.

AU - Fritz, Elizabeth A.

AU - Jahrling, Peter B.

AU - Karp, Christopher L.

AU - Huggins, John W.

AU - Geisbert, Thomas

PY - 2004/2

Y1 - 2004/2

N2 - A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon -β 1a potently inhibits SARS coronavirus replication in vitro.

AB - A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon -β 1a potently inhibits SARS coronavirus replication in vitro.

UR - http://www.scopus.com/inward/record.url?scp=0842325670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842325670&partnerID=8YFLogxK

M3 - Article

C2 - 15030704

AN - SCOPUS:0842325670

VL - 10

SP - 317

EP - 319

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 2

ER -